torasemide ER / Sarfez Pharma - LARVOL DELTA

NEPHRON: A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease (clinicaltrials.gov) - P3 | N=0 | Withdrawn | Sponsor: Sarfez Pharmaceuticals, Inc. | N=30 ➔ 0 | Initiation date: Dec 2025 ➔ May 2025 | Recruiting ➔ Withdrawn

Enrollment change • Trial initiation date • Trial withdrawal • Cardiovascular • Chronic Kidney Disease • Hypertension • Nephrology • Renal Disease

Extended-release Torsemide To Improve Overactive Bladder Symptoms In Chronic Heart Failure: A Randomized, Double-blind, Crossover Pilot Study [Poster no. 664] (HFSA 2026) - No abstract available

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Overactive Bladder

EXTOR-HF: A Crossover Study of Patients With HF to Compare Natriuretic Effects of IR Torsemide vs. ER Torsemide Over 12 Hrs (clinicaltrials.gov) - P4 | N=0 | Withdrawn | Sponsor: Sarfez Pharmaceuticals, Inc. | Terminated ➔ Withdrawn

Trial withdrawal • Cardiovascular • Congestive Heart Failure • Heart Failure

Immediate Release Torsemide Versus Extended Release Torsemide After Salty Meal (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: Sarfez Pharmaceuticals, Inc. | Terminated ➔ Withdrawn

Trial withdrawal • Cardiovascular • Congestive Heart Failure • Heart Failure

Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide (clinicaltrials.gov) - P1 | N=20 | Terminated | Sponsor: Sarfez Pharmaceuticals, Inc. | Completed ➔ Terminated; recruitment issues

Trial termination • Cardiovascular • Congestive Heart Failure • Heart Failure

Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder (clinicaltrials.gov) - P2 | N=24 | Completed | Sponsor: Sarfez Pharmaceuticals, Inc. | Recruiting ➔ Completed | Trial completion date: Jul 2026 ➔ Dec 2025

Trial completion • Trial completion date • Cardiovascular • Congestive Heart Failure • Heart Failure • Overactive Bladder • Urinary Incontinence

NEXT-HF: Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure (clinicaltrials.gov) - P4 | N=20 | Completed | Sponsor: Sarfez Pharmaceuticals, Inc. | Recruiting ➔ Completed

Trial completion • Cardiovascular • Congestive Heart Failure • Heart Failure

Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone (clinicaltrials.gov) - P3 | N=24 | Completed | Sponsor: Sarfez Pharmaceuticals, Inc. | Recruiting ➔ Completed | Trial completion date: Nov 2026 ➔ Feb 2026 | Trial primary completion date: Jun 2026 ➔ Feb 2026

Trial completion • Trial completion date • Trial primary completion date

A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects (clinicaltrials.gov) - P3 | N=24 | Completed | Sponsor: Sarfez Pharmaceuticals, Inc. | Recruiting ➔ Completed | Trial completion date: Jun 2026 ➔ Dec 2025

Trial completion • Trial completion date

Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects (clinicaltrials.gov) - P3 | N=24 | Completed | Sponsor: Sarfez Pharmaceuticals, Inc. | Recruiting ➔ Completed | Trial completion date: Jun 2026 ➔ Dec 2025

Trial completion • Trial completion date

Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Sarfez Pharmaceuticals, Inc. | Trial primary completion date: Jul 2026 ➔ Dec 2025

Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure • Overactive Bladder • Urinary Incontinence

NEPHRON: A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease (clinicaltrials.gov) - P3 | N=30 | Recruiting | Sponsor: Sarfez Pharmaceuticals, Inc.

New P3 trial • Cardiovascular • Chronic Kidney Disease • Hypertension • Nephrology • Renal Disease

Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone (clinicaltrials.gov) - P3 | N=24 | Recruiting | Sponsor: Sarfez Pharmaceuticals, Inc.

New P3 trial

A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects (clinicaltrials.gov) - P3 | N=24 | Recruiting | Sponsor: Sarfez Pharmaceuticals, Inc.

New P3 trial

Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects (clinicaltrials.gov) - P3 | N=24 | Recruiting | Sponsor: Sarfez Pharmaceuticals, Inc.

New P3 trial

NEXT-HF: Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure (clinicaltrials.gov) - P4 | N=20 | Recruiting | Sponsor: Sarfez Pharmaceuticals, Inc.

New P4 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

EXTOR-HF: A Crossover Study of Patients with HF to Compare Natriuretic Effects of IR Torsemide Vs. ER Torsemide Over 12 Hrs (clinicaltrials.gov) - P4 | N=5 | Terminated | Sponsor: Sarfez Pharmaceuticals, Inc. | N=26 ➔ 5 | Trial completion date: Nov 2025 ➔ Mar 2025 | Recruiting ➔ Terminated | Trial primary completion date: Nov 2025 ➔ Mar 2025; Issues with recruitment

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Cardiovascular • Congestive Heart Failure • Heart Failure

Effect of Extended Release Torsemide in Patients with Congestive Heart Failure and Overactive Bladder (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Sarfez Pharmaceuticals, Inc. | Withdrawn ➔ Recruiting | Trial completion date: Mar 2025 ➔ Jul 2026 | Trial primary completion date: Mar 2025 ➔ Jul 2026

Enrollment open • Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure • Overactive Bladder • Urinary Incontinence

Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: Sarfez Pharmaceuticals, Inc. | N=24 ➔ 0 | Recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Cardiovascular • Congestive Heart Failure • Heart Failure • Overactive Bladder • Urinary Incontinence

Immediate Release Torsemide Versus Extended Release Torsemide After Salty Meal (clinicaltrials.gov) - P2 | N=1 | Terminated | Sponsor: Sarfez Pharmaceuticals, Inc. | Withdrawn ➔ Terminated; Issues with recruitment

Trial termination • Cardiovascular • Congestive Heart Failure • Heart Failure

Immediate Release Torsemide Versus Extended Release Torsemide After Salty Meal (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: Sarfez Pharmaceuticals, Inc. | N=26 ➔ 0 | Trial completion date: Aug 2025 ➔ Mar 2025 | Recruiting ➔ Withdrawn | Trial primary completion date: Aug 2025 ➔ Mar 2025

Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Cardiovascular • Congestive Heart Failure • Heart Failure

EXTOR-HF: A Crossover Study of Patients With HF to Compare Natriuretic Effects of IR Torsemide vs. ER Torsemide Over 12 Hrs (clinicaltrials.gov) - P4 | N=26 | Recruiting | Sponsor: Sarfez Pharmaceuticals, Inc.

New P4 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

Immediate Release Torsemide Versus Extended Release Torsemide After Salty Meal (clinicaltrials.gov) - P2 | N=26 | Recruiting | Sponsor: Sarfez Pharmaceuticals, Inc. | Initiation date: Jul 2024 ➔ Nov 2024

Trial initiation date • Cardiovascular • Congestive Heart Failure • Heart Failure

Immediate Release Versus Extended Release Torsemide After Salty Meal (clinicaltrials.gov) - P2 | N=26 | Recruiting | Sponsor: Sarfez Pharmaceuticals, Inc. | Initiation date: Apr 2024 ➔ Jul 2024

Trial initiation date • Cardiovascular • Congestive Heart Failure • Heart Failure

Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide (clinicaltrials.gov) - P1 | N=20 | Completed | Sponsor: Sarfez Pharmaceuticals, Inc. | Unknown status ➔ Completed

Trial completion • Cardiovascular • Congestive Heart Failure • Heart Failure